NEWTON, Mass.--(BUSINESS WIRE)--Feb. 24, 2006--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate-based therapeutic compounds, today announced that Hana Chen-Walden, M.D. is presenting an update of the Company’s Phase II and Phase III clinical trials at the Central European Society for Anti-Cancer Drug (CESAR) Conference being held today in Frankfurt, Germany. Dr. Chen-Walden provides the Company with management of clinical and regulatory activities in Europe.
